loading page

A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia
  • +3
  • Misam Zawit,
  • CARMELO GURNARI,
  • Simona Pagliuca,
  • Hassan Awada,
  • Jaroslaw Maciejewski,
  • Yogen Saunthararajah
Misam Zawit
Cleveland Clinic Foundation
Author Profile
CARMELO GURNARI
University of Rome Tor Vergata
Author Profile
Simona Pagliuca
Cleveland Clinic Foundation
Author Profile
Hassan Awada
Cleveland Clinic Foundation
Author Profile
Jaroslaw Maciejewski
Cleveland Clinic Foundation
Author Profile
Yogen Saunthararajah
Cleveland Clinic Foundation
Author Profile

Abstract

T-cell large granular lymphocytic leukemia (T-LGL) is a chronic malignancy characterized by clonal expansion of cytotoxic T-cells possibly complicated by cytopenias of one or more myeloid lineages. By describing a multiply-refractory T-LGL case, this report highlights the importance of molecular-targeted and non-cytotoxic therapies in the context of frail elderly patients.

Peer review status:UNDER REVIEW

05 May 2021Submitted to Clinical Case Reports
06 May 2021Submission Checks Completed
06 May 2021Assigned to Editor
10 May 2021Reviewer(s) Assigned
15 May 2021Review(s) Completed, Editorial Evaluation Pending
03 Jun 2021Editorial Decision: Revise Minor
04 Jun 20211st Revision Received
05 Jun 2021Submission Checks Completed
05 Jun 2021Assigned to Editor
05 Jun 2021Review(s) Completed, Editorial Evaluation Pending